Obstetrics and Gynecology, Ospedale San Raffaele, Milano, Italy
Università Vita Salute San Raffaele, Milano, Italy.
Int J Gynecol Cancer. 2019 Nov;29(9):1431-1436. doi: 10.1136/ijgc-2019-000624. Epub 2019 Sep 18.
Ovarian cancer relapses have been traditionally classified according to the platinum-free interval, leading to an arbitrary categorization of possible scenarios and treatment options. Its relevance in assessing treatment strategies has been revised in the last several years, as the panorama is constantly changing in the era of personalized medicine and targeted therapies. Factors to be considered while defining the best management of recurrent disease, and, consequently, the available treatment alternatives are increasing. Platinum remains one of the milestones of ovarian cancer treatment, but for some patients it might not be an ideal choice for several reasons other than limited platinum sensitivity. This review aims to analyze the scenarios in which platinum is not considered suitable in the management of patients with recurrent ovarian cancer, and the currently available alternatives.
卵巢癌复发传统上根据无铂间期进行分类，导致可能的治疗方案和治疗选择被任意分类。在个性化医学和靶向治疗时代，这种分类在评估治疗策略方面的相关性已被重新评估，因为治疗方案不断变化。在定义复发性疾病的最佳管理以及相应的治疗选择时，需要考虑的因素正在增加。铂类仍然是卵巢癌治疗的里程碑之一，但对于某些患者，由于铂类敏感性有限等多种原因，铂类可能不是理想的选择。本综述旨在分析在管理复发性卵巢癌患者时不考虑使用铂类的情况，以及目前可用的替代方案。
